美国和欧洲CAP治疗指南比较(英文)课件.ppt

EuropeanCAPGuidelinesHLodeRationaleforAntibioticTherapyGuidelinesEnsureappropriateprescribingPromotetherationaluseofantibioticsLimittheemergenceofresistanceConservenewagentsEnsurecost-;2:161–(%)munity-AcquiredPneumonia(CAP)–Europe(5,961AdultHospitalizedCAPPatientsin26ProspectiveStudiesfrom10EuropeanCountries)Atypicals:25%;113:183S–187SPracticeGuidelinesforCAPYear Country/society1991 France1993 AmericanThoracicSociety(ATS),Canada,UK1995 Italy1997 Spain1998 InfectiousDiseasesSocietyofAmerica(IDSA) EuropeanRespiratorySociety(ERS)2000 CentersforDiseaseControlandPrevention(CDCP), IDSA,CanadianInfectiousDiseasesSociety/Canadian ThoracicSociety(CIDS/CTS),Japan2001 ATSHuchonG,;8:391-,;31:383-,;31:347-,;160:1399-:Tokyo,;163:1730- – Aframeworkfortheevaluationand therapyofthepatientwithCAPERS19982 – Generalguidelinesforthecareofpatients munity-acquiredLRTIsCIDS/CTS20003 – Arationalapproachtotheinitial antimicrobialmanagementofpatientswith CAPCDCP20004 – mendationsforthe managementofCAPandthesurveillance ;163:1730-,;8:391-,;31:383-,;160:1399-—TreatmentOptions(1)ERS Penicillin*,aminopenicillin±-lactamaseinhibitor(especiallyif Hinfluenzaesuspected),macrolide,tetracycline,cephalosporin, quinolone,oralstreptograminIDSA Macrolide,doxycycline,fluoroquinoloneCIDS/CTS Macrolide*,doxycycline COPD,norecentRX Macrolide*,doxycycline COPD,recentRX Fluoroquinolone*, amoxicillin/clavulanate+macrolide Suspected Amoxicil